BOSTON SCIENTIFIC CORP (BSX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net sales | 5,061 | 4,663 | 4,209 | 4,120 |
| Cost of products sold | 1,637 | 1,453 | 1,312 | 1,270 |
| Gross profit | 3,424 | 3,210 | 2,897 | 2,850 |
| Litigation-related net charges (credits) | - | - | - | - |
| Selling, general and administrative expenses | 1,716 | 1,597 | 1,562 | 1,446 |
| Royalty expense | 14 | 14 | 5 | 9 |
| Restructuring net charges (credits) | 83 | 10 | 8 | 1 |
| Research and development expenses | 526 | 443 | 407 | 383 |
| Intangible asset impairment charges | 46 | - | - | 276 |
| Contingent consideration net expense (benefit) | -5 | 5 | -23 | 2 |
| Amortization expense | 225 | 219 | 205 | 213 |
| Operating expenses | 2,605 | 2,288 | 2,164 | 2,330 |
| Operating income (loss) | 819 | 921 | 733 | 520 |
| Interest expense | 90 | 82 | 79 | 77 |
| Other, net | 213 | -34 | - | - |
| Other, net | - | - | 14 | -23 |
| Income (loss)before income taxes | 941 | 805 | 669 | 420 |
| Income tax expense (benefit) | 146 | 133 | 200 | 98 |
| Net income (loss) | 795 | 672 | 468 | 322 |
| Net income (loss) attributable to noncontrolling interests | -2 | -2 | - | -2 |
| Preferred stock dividends | - | - | - | - |
| Net income (loss) attributable to boston scientific common stockholders | 797 | 674 | 469 | 324 |
| Basic | 1,479,900,000 | 1,477,200,000 | 1,472,700,000 | 1,470,600,000 |
| Diluted | 1,493,500,000 | 1,493,100,000 | 1,487,400,000 | 1,484,200,000 |
| Net income (loss)per common share basic | 0.54 | 0.46 | 0.32 | 0.22 |
| Net income (loss)per common share diluted | 0.53 | 0.45 | 0.32 | 0.22 |